Innovative therapeutic actions by targeting serotonin 1A receptors selectively

References

• Aghajanian G.K., Vandermaelen C.P. Intracellular recordings from serotonergic dorsal raphe neurons: pacemaker potentials and the effect of LSD. Brain Research 1982; 238: 463–469
   Google Scholar
• Aghajanian G.K., Lakoski J.M. Hyperpolarization of serotonergic neurons by serotonin and LSD: studies in brain slices showing increased K+ conductance. Brain Research 1984; 305: 181–185
   PubMedGoogle Scholar
• Aghajanian G.K., Sprouse J.S., Rasmussen K. Physiology of the midbrain serotonin system. Psychopharmacology: A Third Generation of Progress, H. Meltzer. Raven, New York 1987; 141–149
   Google Scholar
• Aprison M.H., Hingtgen J.N. Hypersensitive serotonergic receptors: a new hypothesis for one subgroup of unipolar depression derived from an animal model. Serotonin—Current Aspects of Neurochemistry and Function, B. Haber, S. Gabay, S. Alivisatos, M. Issidorides. Plenum Press, New York 1981; 627–656
   Google Scholar
• Araneda R., Andrade R. 5-Hydrox-ytryptamine2 and 5-HydroxytryptamineIA receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 1991; 40: 399–412
   PubMed Web of Science ®Google Scholar
• Arborelius L., Backlund Hook B., Hacksell U., Svensson T.H. The 5-HTIA receptor antagonist (S)-UH-301 blocks the (R)-8-OH-DPAT—induced inhibition of serotonergic dorsal raphe cell firing in the rat. Journal of Neurological Transmission 1994; 96: 179–186
   Google Scholar
• Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archives of General Psychiatry 1994; 51: 248–251
   PubMed Web of Science ®Google Scholar
• Ashby C.R., Edwards E., Wang R.Y. Electrophysiological evidence for a functional interaction between 5-HT2A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse 1994; 17: 173–181
   Google Scholar
• Backus L.I., Sharp T., Grahame-Smith D.G. Behavioral evidence for a functional interaction between central 5-HT2 and 5-HTIA receptors. British Journal of Pharmacology 1990; 100: 793–799
   Google Scholar
• Ballenger J.C., Goodwin F.K., Major L.F., Brown G.L. Alcohol and central serotonin metabolism in man. Archives of General Psychiatry 1979; 36: 224–227
   PubMed Web of Science ®Google Scholar
• Berendsen H.H.G., Broekkamp C.L.E. Behavioral evidence for functional interactions between 5-HT-receptor subtype in rats and mice. British Journal of Pharmacology 1990; 101: 667–673
   PubMedGoogle Scholar
• Bianchi C., Siniscalchi A., Bcani L. 5-HTIA agonists increase and 5-HT3 agonists decrease acetylcholine efflux from the cerebral cortex of freely-moving guinea-pigs. British Journal of Pharmacology 1990; 101: 448–452
   Google Scholar
• Blier P., de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HTIA agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987; 1: 470–480
   PubMed Web of Science ®Google Scholar
• Buer P., Lista A., deMontigny C. Differential properties of pre- and postsynaptic 5-hydroxytryptamineIA receptors: I. Effect of spiperone. Journal of Pharmacology and Experimental Therapeutics 1993a; 265: 7–15
   Google Scholar
• Blier P., Lista A., de Montigny C. Differential properties of pre- and postsynaptic 5-hydroxytryptamineIA receptors: II Effect of pertussis and cholera toxins. Journal of Pharmacology and Experimental Therapeutics 1993b; 265: 16–23
   Google Scholar
• Blier P., Seletti B., Bouchard C., Artigas F., de Montigny C.C. Functional evidence for the differential responsiveness of pre- and postsynaptic 5-HTIA receptors in the brain. Society for Neuroscience Abstracts 1994; 20: 1540
   Google Scholar
• Briley M., Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clinical Neuropharmacology 1993; 5: 387–400
   Google Scholar
• Brocco M.J., Kock W., Degryse A.-D., Colpaert F.C. Comparative studies on the anti-punishment effects of chlordiazepoxide, buspirone and ritanserin in the pigeon, Geller-Seifter and Vogel conflict procedures. Behavioral Pharmacology 1990; 1: 403–418
   Google Scholar
• Bruno F. Buspirone in the treatment of alcoholic patients. Psychopharmacology 1989; 22: 49–59, suppl
   Google Scholar
• Carli M., Tatarczynska E., Cervo L., Samanin R. Stimulation of hippocampal 5-HTIA receptors causes amnesia and anxiolytic-like but not antidepressant-like effects in the rat. European Journal of Pharmacology 1993; 234: 215–221
   PubMed Web of Science ®Google Scholar
• Ceulemans D.L.S., Hoppenbrouwers M.-L., Gelders Y.G., Reyntjens A.J.M. The influence of ritanserin, a double-blind placebo-controlled study vs. lorazepam. Pharmacopsychiatry 1985; 18: 303–305
   PubMed Web of Science ®Google Scholar
• Cliffe I.A., Fletcher A. Advances in 5-HTIA antagonist research. Drugs of the Future 1993; 18: 631–642
   Google Scholar
• Cliffe I.A., Brightwell C.I., Fletcher A., et al. (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide (S)-WAY-100,135: a selective antagonist at presynaptic and postsynaptic 5-HTIA receptors. Journal of Medical Chemistry 1993; 36: 1509–1510
   PubMed Web of Science ®Google Scholar
• Cox R.F., Meller E., Waszczak B.L. Electrophysiological evidence for a large receptor reserve for inhibition of dorsal raphe cell firing by 5-HTIA agonists. Synapse 1993; 14: 297–304
   Google Scholar
• Darmani N.A., Martin B.R., Pandey U., Glennon R.A. Do functional relationships between 5-HTIA and 5-HT2 receptors exist?. Pharmacology, Biochemistry and Behavior 1990; 36: 901–906
   Google Scholar
• Deakin J.F.W. 5-HTIA receptors, depression and anxiety. Pharmacology, Biochemistry and Behavior 1988; 29: 819–820
   PubMedGoogle Scholar
• de Montigny C., Chaput Y., Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. Journal of Clinical Psychiatry 1990; 51(suppl B)4–8
   Google Scholar
• Fletcher A., Bill D.J., Bill S.J., Cliffe I.A., Dover G.M., Forster E.A., Haskins J.T., Jones D., Mansell H.L., Reilly Y. WAY-100,135: a novel, selective antagonist at presynaptic and postsynaptic 5-HTIA receptors. European Journal of Pharmacology 1993; 237: 283–291
   PubMed Web of Science ®Google Scholar
• Fornal C.A., Metzler C.W., Gallegos R.A., Veasey S.C., McCreary A.C., Jacobs B.L. WAY-100,635, a potent and selective 5-HTIA receptor antagonist, increases serotonergic neuronal activity and blocks the action of 8-OH-DPAT in behaving cats. Society for Neuroscience Abstracts 1994; 20: 1544
   Google Scholar
• Garratt J., Kidd E.J., Wright I.K., Marsden C.A. Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist, DOI. European Journal of Pharmacology 1991; 199: 349–355
   Google Scholar
• Gleeson S., Ahlers S.T., Mansbach R.S., Foust J.M., Barrett J.E. Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 1989; 250: 809–817
   Google Scholar
• Gray J.A. The Neuropsychology of Anxiety: An Enquiry into the Functions of the Septc-hippocampal System. Oxford University Press, Oxford 1986
   Google Scholar
• Haigler H.J., Aghajanian G.K. Peripheral serotonin antagonists: failure to antagonize serotonin in brain areas receiving a prominent serotonergic input. Journal of Neural Transmission 1974; 35: 257–273
   Web of Science ®Google Scholar
• Hillver S.-E., Bjork L., Li Y.-L., et al. (S)5-Fluro-8-hydroxy-2-(dipropylamino)tetralin: a putative 5-HTIA receptor antagonist. Journal of Medical Chemistry 1990; 33: 1541–1544
   Google Scholar
• Jenkie M.A., Baer L. An open trial of buspirone in obsessive-compulsive disorder. American Journal of Psychiatry 1988; 145: 1285–1286
   Google Scholar
• Lakoski J.M., Aghajanian G.K. Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology 1985; 24: 265–273
   Google Scholar
• Lee E.H.Y., Lin W.R., Chen H.Y., Shiu W.H., Liang K.C. Fluoxetine and 8-OH-DPAT in the lateral septum enhances and impairs retention of an inhibitory avoidance response in rats. Physiology and Behavior 1992; 51: 681–688
   Google Scholar
• Lejeune F., Rivet J.-M., Gobert A., Canton H., Millan M.J. WAY-100,135 and (–)-tertatolol act as antagonists at both 5-HTIA autoreceptors and postsynaptic 5-HTIA receptors in vivo. European Journal of Pharmacology 1993; 221: 307–310
   Google Scholar
• Mansbach R.S., Harrod C., Hoffmann S.M., Nader M.A., Lei Z., Witkin J.M., Barrett J.E. Behavioral studies with anxiolytic drugs. V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished responding. Journal of Pharmacology and Experimental Therapeutics 1988; 246: 114–120
   Google Scholar
• Mansbach R.S., Geyer M.A. Blockade of potentiated startle responding in rats by 5-hydroxy-tryptamineIA receptor ligands. European Journal of Pharmacology 1988; 156: 375–383
   PubMed Web of Science ®Google Scholar
• Meller E., Goldstein M., Bohmaker K. Receptor reserve for 5-hydroxytryptamineIA-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxy-tryptamineIA agonists. Molecular Pharmacology 1990; 37: 231–237
   PubMed Web of Science ®Google Scholar
• Olivera A.A., Sarvis S., Heard C. Anxiety disorders coexisting with substance dependence: treatment with buspirone. Current Therapeutic Research 1990; 47: 52–60
   Web of Science ®Google Scholar
• Pato M.T., Pigott T.A., Hill J.L., Grover G., Bernstein S.E., et al (1989) Clomipramine vs. buspirone in OCD: a controlled trial. New Research Program and Abstracts of the Annual Meeting of the American Psychiatric Association, San Francisco, May, 6–111989, 34
   Google Scholar
• Pazos A., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the brain. I. Serotonin-1 receptors. Brain Research 1985; 346: 205–230
   PubMed Web of Science ®Google Scholar
• Pazos A., Cortes R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the brain. U. Serotonin-2 receptors. Brain Research 1985; 346: 231–249
   PubMed Web of Science ®Google Scholar
• Pedigo N.W., Yamamura H.I., Nelson D.L. Discrimination of multiple [3H]-5-hydrox-ytryptamine binding sites by the neuroleptic spiperone in rat brain. Journal of Neurochemistry 1981; 36: 220–226
   PubMed Web of Science ®Google Scholar
• Pohl R., Balon R., Yeragani V.K., Gershon S. Serotonergic anxiolytics in the treatment of panic disorder, a controlled study with buspirone. Psychopathology 1989; 22(Suppl. 1)60–67
   Google Scholar
• Privette T.H., Hornsby R.L., Meyers R.D. Buspirone alters alcohol drinking induced in rats by tetrahydropapervoline injected into brain monoaminergic pathways. Alcohol 1987; 5: 147–152
   Google Scholar
• Radia F., Daval G., Hamon M., Vergé D. Pharmacological and physiochemical properties of pre- versus postsynaptic 5-hydroxy-tryptamineIA receptor binding sites in the rat brain: aquantitative autoradiographic study. Journal of Neurochemistry 1992; 58: 1338–1346
   Google Scholar
• Rigdon G.C., Weatherspoon J.K. 5-HTIA receptor agonists block prepulse inhibition of acoustic startle reflex. Journal of Pharmacology and Experimental Therapeutics 1992; 263: 486–493
   PubMed Web of Science ®Google Scholar
• Rowan M.J., Cullen W.K., Moulton B. Buspirone impairment of performance of passive avoidance and spatial learning tasks in the rat. Psychopharmacology 1990; 100: 393–398
   PubMedGoogle Scholar
• Roy A., Virkkunen M., Linnoila M. Reduced central serotonin turnover in a subgroup of alcoholics. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1987; 11: 173–177
   PubMed Web of Science ®Google Scholar
• Schmidt C.J., Kehne J.H., Moser P.C., Sorensen S.M. Preclinical antipsychotic activity of die selective 5-HTIA antagonist, MDL-100,907. Neuropsychopharmacology 1994; 10: 27, Number 3S/Part 3
   Google Scholar
• Sharp T., Bramwell S.R., Grahame-Smith D.G. In vivo measurements of brain extracellular 5-hydroxytryptamine using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. Journal of Neurochemistry 1989; 53: 234–240
   PubMedGoogle Scholar
• Shen Y., Monsma F. J., Jr., Metcalf M.A., Jose P.A., Hamblin M.W., Sibley D.R. Molecular cloning and expression of a 5-hydroxy-tryptamine7 serotonin receptor subtype. Journal of Biological Chemistry 1993; 268: 18200–18204
   PubMed Web of Science ®Google Scholar
• Smith L.M., Peroutka S.J. Differential effects of 5-hydroxytryptamineIA selective drugs on the 5-HT behavioral syndrome. Pharmacology, Biochemistry and Behavior 1986; 24: 1513–1519
   PubMed Web of Science ®Google Scholar
• Sprouse J.S., Aghajanian G.K. (–)-Propranolol blocks die inhibition of serotonergic dorsal raphe cell firing by 5-HTIA selective agonists. European Journal of Pharmacology 1986; 128: 295–298
   Google Scholar
• Sprouse J.S., Aghajanian G.K. Electrophysiological responses of serotonergic dorsal raphe neurons to 5-HTIA and 5-HTIB agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 1987; 27: 707–715
   Google Scholar
• Sprouse J.S., Aghajanian G.K. Responses of hippocampal pyramidal cells to putative sertotonin 5-HTIA and 5-HTIB agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 1988; 27: 707–715
   PubMed Web of Science ®Google Scholar
• Stutzmann J.M., Eon B., Darche F., Lucas M., Rataud J., Piot O., Blanchard J.C., Laduron P.M. Are 5-HT2 antagonists endowed with anxiolytic properties in rodents?. Neuroscience Letters 1991; 128: 4–8
   Google Scholar
• Tollefson G.D., Montague-Clouse J., Lancaster S.P. Buspirone in comorbid alcohol dependency and generalized anxiety disorders. Drug Therapy 1990; 20: 35–50, suppl
   Google Scholar
• Tomkins E.C., Clbmento A.J., Taylor D.P., Perhach J.L. Inhibition of aggressive behavior in rhesus monkeys by buspirone. Research Communications in Psychology and Psychiatric Behavior 1980; 5: 337–352
   Google Scholar
• Traber J., Glaser T. 5-HTIA receptor-related anxiolytics. Trends in Pharmacological Sciences 1987; 8: 432–437
   Web of Science ®Google Scholar
• Vergé D., Daval G., Patey A., Gozlan H., El Mestikawy S., Hamon M. Presynaptic 5-HT autoreceptors on serotonergic cell bodeies and/or dendrites but not terminals are of the 5-HTIA subtype. European Journal of Pharmacology 1985; 113: 463–464
   PubMed Web of Science ®Google Scholar
• Vergé D., Daval G., Marcdmkiewicz M., Patey A., El Mestocawy S., Gozlan H., Hamon M. Quantitative autoradiography of multiple 5-HTi receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. Journal of Neuroscience 1986; 6: 3474–3482
   Google Scholar
• Weissmann-Nanopoulos D., Mach E., Magre J., Demassey Y., Pujol J.F. Evidence for die localization of 5-HTIA binding sites on serotonin containing neurons in die raphe dorsalis and raphe centralis nuclei of die rat brain. Neurochemistry International 1985; 7: 1061–1072
   Google Scholar
• Wilkinson L.O., Dourish C.T. Serotonin and animal behavior. Serotonin Receptor Subtypes: Basic and Clinical Aspects, S.J. Peroutka. Wiley-Liss, Inc., New York 1991; 147–210
   Google Scholar
• Wilkinson L.O., Hutson P.H., Middlemiss D.N. 5-HTIA receptor agonists increase hippocampal ACh efflux and locomotion in guinea pig via 5-HTIA receptors. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 656–664
   Google Scholar
• Winter J.C., Petti D.T. The effects of 8-Hydroxy-2-(di-n-propylamino)tetralin and other serotonergic agonists on performance in a radial maze: a possible role for 5-HTIA receptors in memory. Pharmacology, Biochemistry and Behavior 1987; 27: 625–628
   Google Scholar
• Wood P., Nair N.P.V., Lal S., Etienne P. Buspirone, a potential atypical neuroleptic. Life Sciences 1983; 33: 269–273
   PubMed Web of Science ®Google Scholar
• Yocca F.D., Iben L., Meller E. Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamineIA receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes. Molecular Pharmacology 1992; 41: 1066–1072
   PubMed Web of Science ®Google Scholar